The examination of the extracellular environment of NM23 and the molecule target therapy in malignant lymphoma

点击翻译按钮获取中文摘要

We examined whether nm23-H1 is a prognostic factor of DLBCL in the rituximab-era. The subjects were DLBCL patients who underwent chemotherapy and in whom markers could be analyzed. Among DLBCL patients who underwent chemotherapy, BCL2-positivity, MUM1-positivity, non-GCB, and nm23-H1-positivity were associated with significantly shorter overall survival and progression-free survival. We demonstrated that among patients with DLBCL who underwent chemotherapy, patients with nm23-H1 expression had a significantly poorer prognosis than patients without nm23-H1 expression. These results suggest an important role for nm23-H1 in malignant progression and a potential therapeutic target for DLBCL.